Praxis Precision Medicine Q3 EPS $(0.18) Beats $(0.35) Estimate, Sales $468.00K; Cash Of $101.1M Supports Runway Into Q1 2025
Portfolio Pulse from Benzinga Newsdesk
Praxis Precision Medicine (NASDAQ:PRAX) reported Q3 losses of $(0.18) per share, beating the analyst consensus estimate of $(0.35) by 48.57%. This is an 81.25% increase over losses from the same period last year. The company reported $468.00K in sales this quarter. The company's cash of $101.1M supports its runway into Q1 2025.
November 07, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Praxis Precision Medicine reported better than expected Q3 earnings, with losses per share of $(0.18), beating estimates by 48.57%. The company also reported $468.00K in sales and has a cash reserve of $101.1M, which supports its operations until Q1 2025.
Praxis Precision Medicine reported better than expected Q3 earnings, which is a positive signal for investors. The company's losses per share decreased significantly compared to the same period last year, indicating improved financial performance. Additionally, the company's substantial cash reserve provides financial stability and supports its operations until Q1 2025, which is likely to boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100